Chile-based biotechnology company PhageLab secures $11M in funding. Nazca, Collaborative Fund, Water Lemon Ventures, and private investor Kevin Efrusy were among the backers.
With the funding, the company hopes to expand its pipeline of phage-based treatments, take a firm commercial foothold in Brazil, its primary target market, and introduce its technology to the US.
Read also – MA-based 3Daughters Secures Over $2M in Seed Funding
PhageLab is a biotechnology firm led by CEO Hans Pieringer that creates tailored bacteriophage therapies to lessen the abuse of antibiotics to control germs in cattle breeding procedures.
The company was established in 2010 and has created a microbial bioinformatics platform for the development of medicines based on bacteriophages. Using artificial intelligence (AI), the platform creates “customised cocktails” that can efficiently control harmful germs in the cattle sector and lessen reliance on antibiotics.
Read also – CA-based PowerSchool Acquired Allovue
One of the biggest industrial bacterial databases in the world was created using the training dataset for this platform, which is based on more than ten years of experimentation data and validated phage repositories. Using this library, PhageLab can produce safe and efficient tailored solutions in 45 days to eradicate germs in cattle.
About PhageLab
Phagelab, With over a decade of experience in creating medicines based on bacteriophages, their lab is of the highest calibre. Their sole objective is to safeguard the global health of all people. It is the only way to address the widespread problem of antibiotic resistance brought on by its careless usage, which has an impact on millions of lives every day, everywhere.
Read also – R.I.-based Bolden Therapeutics, Inc. Secures $1.5M in Pre-Seed Convertible Note Funding
